SeekingAlpha  Apr 10  Comment 
ByPropThink: By Jake King When Mr. Deryugin penned his original thoughts on Acorda Therapeutics (ACOR) in mid-2013, the stock traded around $38. While investors heeding his advice sit slightly in the green today, we believe the thesis holds with...
SeekingAlpha  Feb 22  Comment 
ByFuturistics: Acorda Therapeutics, Inc. (ACOR) shares are trading at around $36 and generated a 16% return last year. They have the potential to deliver around a 50% return this year. The following reasons could be cited as the potential...
SeekingAlpha  Feb 13  Comment 
Acorda Therapeutics, Inc. (ACOR) Q4 2013 Earnings Conference Call February 13, 2014 8:30 am ET Executives Ron Cohen - President and Chief Executive Officer Michael Rogers - Chief Financial Officer Jeff Macdonald - IR ...
DailyFinance  Jan 13  Comment 
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2013 were $84 million, and unaudited AMPYRA 2013 full-year net...
DailyFinance  Jan 7  Comment 
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the upcoming 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014 at 11:00 a.m. Pacific Time...
Benzinga  Jan 6  Comment 
In a report published on Monday, lead analyst Yaron Werber downgraded Acorda Therapeutics (NASDAQ: ACOR) from Buy to Neutral and lowered their price target to $33 from $37. Werber noted, “We have made comprehensive changes to our model and as...
Market Intelligence Center  Jan 3  Comment 
The patented option trade-picking algorithms behind MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered call trade on Acorda Therapeutics (ACOR) that includes 10.19% downside protection. Sell one contract of the...
DailyFinance  Dec 19  Comment 
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the European Patent Office (EPO) Opposition Division has upheld amended claims covering a sustained release formulation of fampridine (known under the trade name...
Benzinga  Dec 9  Comment 
Acorda Therapeutics (Nasdaq: ACOR) today announced that new data from a pharmacokinetics study on Diazepam Nasal Spray found comparable pharmacokinetics (PK) whether the drug was administered during or immediately after a...
Market Intelligence Center  Dec 5  Comment 
Acorda Therapeutics (ACOR) presents a trading opportunity that offers a 9.89% return in just 135 days. A covered call on Acorda Therapeutics at the $32.00 level expiring on Apr. '14 offers an assigned return rate of 9.89% or 26.74% annualized....


Acorda Therapeutics (NYSE: ACOR) is a biotechnology company specializing in therapies designed to improve the quality of life for multiple sclerosis (MS) patients. The company has two major products currently approved for sale. Acorda launched Zanaflex capsules in 2005 to relieve spasms in MS patients, and received FDA approval for Ampyra in 2010 to improve walking in MS patients. Ampyra is currently Acorda's biggest revenue generator, with $141 million in 2010 sales.

Ampyra is the driver of Acorda's revenue for the near-term future, and its sales growth as it ramps up to its peak potential will significantly impact Acorda's value. In addition, Acorda is pursuing patent extension opportunities that could protect it from generic competition for the next decade.

Business Growth

FY 2010 (ended December 31, 2010)

  • Net revenue more than tripled to $182 million.
  • Net loss decreased 86% to $11.8 million.

In 2010, revenue growth was driven by the approval of Ampyra by the FDA to improve walking in adults with multiple sclerosis (MS).[1] In 2010, its first year of commercial sales, Ampyra earned $141 million in revenue. Acorda's other major drug, Zanaflex, which is used to relieve spasms in MS patients, earned $55 million, a decrease of 6%.[2] For 2011, Acorda expects net revenue to increase to $205-230 million.[3]

Trends and Forces

Ampyra Sales Growth Will Define Acorda's Success

The FDA approval of Ampyra to treat MS has transformed Acorda's business. As sales for Ampryria ramp up to the $871 million that analysts expect for 2015, these sales will make up the vast majority of Acorda revenue.[4] In 2010, Ampyra garnered $141 million in sales and analysts expect as much as $230 million in sales for 2011. How Acorda ramps up sales of Ampyra and where peak sales fall relative to analyst estimates will impact Acorda's valuation.[5]

Acorda's Ability to Retain Patent Exclusivity for Ampyra will Impact Revenue

As a treatment for a rare disease, Ampyra has been granted 7 years of "Orphan Drug" exclusivity by the FDA for the treatment of MS. However, the major patents for Ampyra, which are necessary to prevent competitors from developing the drug for other disease markets, expire in 2011 and 2013. In 2010, Acorda applied for extensions on the patents, which would grant the company 5 additional years of exclusivity.[6] Acorda's ability to gain these extensions will impact its ability to prevent competition in markets outside of the MS field.


There are currently no generic versions of Ampyra, and FDA Orphan Drug regulations will prevent competition from entering the MS market until at least 2017.


  1. FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
  2. ACOR 2011 10K
  3. Acorda Therapeutics Reports Fourth Quarter and Full Year 2010 Financial Results
  4. Acorda shares soar on possible patent extension of MS drug
  5. Acorda Pushes Sales of MS Drug
  6. Acorda Therapeutics Announces Filing Of Patent Extension Applications For AMPYRA
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki